{"id":893691,"date":"2025-10-08T08:30:56","date_gmt":"2025-10-08T12:30:56","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/mltx-inquiry-notice-moonlake-immunotherapeutics-hit-with-securities-fraud-investigation-due-to-drug-trial-results-contact-bfa-law\/"},"modified":"2025-10-08T08:30:56","modified_gmt":"2025-10-08T12:30:56","slug":"mltx-inquiry-notice-moonlake-immunotherapeutics-hit-with-securities-fraud-investigation-due-to-drug-trial-results-contact-bfa-law","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/mltx-inquiry-notice-moonlake-immunotherapeutics-hit-with-securities-fraud-investigation-due-to-drug-trial-results-contact-bfa-law\/","title":{"rendered":"MLTX INQUIRY NOTICE: MoonLake Immunotherapeutics Hit with Securities Fraud Investigation Due to Drug Trial Results — Contact BFA Law"},"content":{"rendered":"
\n

NEW YORK, Oct. 08, 2025 (GLOBE NEWSWIRE) — Leading securities law firm\u00a0Bleichmar Fonti & Auld LLP<\/strong><\/a> announces an investigation into MoonLake Immunotherapeutics (NASDAQ: MLTX) for potential violations of the federal securities laws.<\/p>\n

If you invested in MoonLake, you are encouraged to obtain additional information by visiting: https:\/\/www.bfalaw.com\/cases\/moonlake-immunotherapeutics<\/strong><\/a>.<\/p>\n

\n Why Is MoonLake being Investigated?<\/strong>\n <\/p>\n

MoonLake is a clinical stage biotechnology company focusing on therapies to address inflammatory skin and joint diseases. During the relevant period, MoonLake conducted highly anticipated Phase 3 VELA trials for sonelokimab, an investigational therapeutic designed to treat inflammatory diseases, in adult participants with moderate to severe hidradenitis suppurativa.<\/p>\n

On September 29, 2025, before market hours, MoonLake reported its week 16 results of the VELA Phase 3 trials. The company reported disappointing results for both trials, calling into question the drug\u2019s chances for regulatory approval and commercial viability. On this news, the price of MoonLake stock fell $55.75 per share, or nearly 90%, from $61.99 per share on September 28, 2025, to $6.24 per share on September 29, 2025.<\/p>\n

\n Click here for more information: <\/strong>
\n
\n https:\/\/www.bfalaw.com\/cases\/moonlake-immunotherapeutics<\/strong>
\n <\/a>
\n .<\/strong>\n <\/p>\n

\n What Can You Do?<\/strong>\n <\/p>\n

If you invested in MoonLake you may have legal options and are encouraged to submit your information to the firm.<\/p>\n

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.<\/p>\n

\n Submit your information by visiting:<\/strong>\n <\/p>\n

\n
\n https:\/\/www.bfalaw.com\/cases\/moonlake-immunotherapeutics<\/strong>
\n <\/a>\n <\/p>\n

Or contact:
Ross Shikowitz
ross@bfalaw.com<\/a>
212.789.3619<\/p>\n

\n Why Bleichmar Fonti & Auld LLP?<\/strong>\n <\/p>\n

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA<\/em>, The Legal 500<\/em>, and ISS SCAS<\/em>, and its attorneys have been named \u201cElite Trial Lawyers\u201d by the National Law Journal<\/em>, among the top \u201c500 Leading Plaintiff Financial Lawyers\u201d by Lawdragon<\/em>, \u201cTitans of the Plaintiffs\u2019 Bar\u201d by Law360<\/em> and \u201cSuperLawyers\u201d by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.\u2019s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.<\/p>\n

For more information about BFA and its attorneys, please visit https:\/\/www.bfalaw.com<\/a>.<\/p>\n

\n
\n https:\/\/www.bfalaw.com\/cases\/moonlake-immunotherapeutics<\/strong>
\n <\/a>\n <\/p>\n

\n Attorney advertising. Past results do not guarantee future outcomes.<\/em>\n <\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

NEW YORK, Oct. 08, 2025 (GLOBE NEWSWIRE) — Leading securities law firm\u00a0Bleichmar Fonti & Auld LLP announces an investigation into MoonLake Immunotherapeutics (NASDAQ: MLTX) for potential violations of the federal securities laws. If you invested in MoonLake, you are encouraged to obtain additional information by visiting: https:\/\/www.bfalaw.com\/cases\/moonlake-immunotherapeutics. Why Is MoonLake being Investigated? MoonLake is a clinical stage biotechnology company focusing on therapies to address inflammatory skin and joint diseases. During the relevant period, MoonLake conducted highly anticipated Phase 3 VELA trials for sonelokimab, an investigational therapeutic designed to treat inflammatory diseases, in adult participants with moderate to severe hidradenitis suppurativa. On September 29, 2025, before market hours, MoonLake reported its week 16 results of the VELA Phase 3 trials. The … <\/p>\n

Continue reading “MLTX INQUIRY NOTICE: MoonLake Immunotherapeutics Hit with Securities Fraud Investigation Due to Drug Trial Results — Contact BFA Law”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-893691","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nMLTX INQUIRY NOTICE: MoonLake Immunotherapeutics Hit with Securities Fraud Investigation Due to Drug Trial Results - Contact BFA Law - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/mltx-inquiry-notice-moonlake-immunotherapeutics-hit-with-securities-fraud-investigation-due-to-drug-trial-results-contact-bfa-law\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MLTX INQUIRY NOTICE: MoonLake Immunotherapeutics Hit with Securities Fraud Investigation Due to Drug Trial Results - Contact BFA Law - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, Oct. 08, 2025 (GLOBE NEWSWIRE) — Leading securities law firm\u00a0Bleichmar Fonti & Auld LLP announces an investigation into MoonLake Immunotherapeutics (NASDAQ: MLTX) for potential violations of the federal securities laws. If you invested in MoonLake, you are encouraged to obtain additional information by visiting: https:\/\/www.bfalaw.com\/cases\/moonlake-immunotherapeutics. Why Is MoonLake being Investigated? MoonLake is a clinical stage biotechnology company focusing on therapies to address inflammatory skin and joint diseases. During the relevant period, MoonLake conducted highly anticipated Phase 3 VELA trials for sonelokimab, an investigational therapeutic designed to treat inflammatory diseases, in adult participants with moderate to severe hidradenitis suppurativa. On September 29, 2025, before market hours, MoonLake reported its week 16 results of the VELA Phase 3 trials. The … Continue reading "MLTX INQUIRY NOTICE: MoonLake Immunotherapeutics Hit with Securities Fraud Investigation Due to Drug Trial Results — Contact BFA Law"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/mltx-inquiry-notice-moonlake-immunotherapeutics-hit-with-securities-fraud-investigation-due-to-drug-trial-results-contact-bfa-law\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-08T12:30:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU0MTg3NSM3MTg0NzA1IzIyOTA5OTU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mltx-inquiry-notice-moonlake-immunotherapeutics-hit-with-securities-fraud-investigation-due-to-drug-trial-results-contact-bfa-law\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mltx-inquiry-notice-moonlake-immunotherapeutics-hit-with-securities-fraud-investigation-due-to-drug-trial-results-contact-bfa-law\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"MLTX INQUIRY NOTICE: MoonLake Immunotherapeutics Hit with Securities Fraud Investigation Due to Drug Trial Results — Contact BFA Law\",\"datePublished\":\"2025-10-08T12:30:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mltx-inquiry-notice-moonlake-immunotherapeutics-hit-with-securities-fraud-investigation-due-to-drug-trial-results-contact-bfa-law\\\/\"},\"wordCount\":402,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mltx-inquiry-notice-moonlake-immunotherapeutics-hit-with-securities-fraud-investigation-due-to-drug-trial-results-contact-bfa-law\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU0MTg3NSM3MTg0NzA1IzIyOTA5OTU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mltx-inquiry-notice-moonlake-immunotherapeutics-hit-with-securities-fraud-investigation-due-to-drug-trial-results-contact-bfa-law\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mltx-inquiry-notice-moonlake-immunotherapeutics-hit-with-securities-fraud-investigation-due-to-drug-trial-results-contact-bfa-law\\\/\",\"name\":\"MLTX INQUIRY NOTICE: MoonLake Immunotherapeutics Hit with Securities Fraud Investigation Due to Drug Trial Results - Contact BFA Law - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mltx-inquiry-notice-moonlake-immunotherapeutics-hit-with-securities-fraud-investigation-due-to-drug-trial-results-contact-bfa-law\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mltx-inquiry-notice-moonlake-immunotherapeutics-hit-with-securities-fraud-investigation-due-to-drug-trial-results-contact-bfa-law\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU0MTg3NSM3MTg0NzA1IzIyOTA5OTU=\",\"datePublished\":\"2025-10-08T12:30:56+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mltx-inquiry-notice-moonlake-immunotherapeutics-hit-with-securities-fraud-investigation-due-to-drug-trial-results-contact-bfa-law\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mltx-inquiry-notice-moonlake-immunotherapeutics-hit-with-securities-fraud-investigation-due-to-drug-trial-results-contact-bfa-law\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mltx-inquiry-notice-moonlake-immunotherapeutics-hit-with-securities-fraud-investigation-due-to-drug-trial-results-contact-bfa-law\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU0MTg3NSM3MTg0NzA1IzIyOTA5OTU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU0MTg3NSM3MTg0NzA1IzIyOTA5OTU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mltx-inquiry-notice-moonlake-immunotherapeutics-hit-with-securities-fraud-investigation-due-to-drug-trial-results-contact-bfa-law\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MLTX INQUIRY NOTICE: MoonLake Immunotherapeutics Hit with Securities Fraud Investigation Due to Drug Trial Results — Contact BFA Law\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MLTX INQUIRY NOTICE: MoonLake Immunotherapeutics Hit with Securities Fraud Investigation Due to Drug Trial Results - Contact BFA Law - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/mltx-inquiry-notice-moonlake-immunotherapeutics-hit-with-securities-fraud-investigation-due-to-drug-trial-results-contact-bfa-law\/","og_locale":"en_US","og_type":"article","og_title":"MLTX INQUIRY NOTICE: MoonLake Immunotherapeutics Hit with Securities Fraud Investigation Due to Drug Trial Results - Contact BFA Law - Market Newsdesk","og_description":"NEW YORK, Oct. 08, 2025 (GLOBE NEWSWIRE) — Leading securities law firm\u00a0Bleichmar Fonti & Auld LLP announces an investigation into MoonLake Immunotherapeutics (NASDAQ: MLTX) for potential violations of the federal securities laws. If you invested in MoonLake, you are encouraged to obtain additional information by visiting: https:\/\/www.bfalaw.com\/cases\/moonlake-immunotherapeutics. Why Is MoonLake being Investigated? MoonLake is a clinical stage biotechnology company focusing on therapies to address inflammatory skin and joint diseases. During the relevant period, MoonLake conducted highly anticipated Phase 3 VELA trials for sonelokimab, an investigational therapeutic designed to treat inflammatory diseases, in adult participants with moderate to severe hidradenitis suppurativa. On September 29, 2025, before market hours, MoonLake reported its week 16 results of the VELA Phase 3 trials. The … Continue reading \"MLTX INQUIRY NOTICE: MoonLake Immunotherapeutics Hit with Securities Fraud Investigation Due to Drug Trial Results — Contact BFA Law\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/mltx-inquiry-notice-moonlake-immunotherapeutics-hit-with-securities-fraud-investigation-due-to-drug-trial-results-contact-bfa-law\/","og_site_name":"Market Newsdesk","article_published_time":"2025-10-08T12:30:56+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU0MTg3NSM3MTg0NzA1IzIyOTA5OTU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mltx-inquiry-notice-moonlake-immunotherapeutics-hit-with-securities-fraud-investigation-due-to-drug-trial-results-contact-bfa-law\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mltx-inquiry-notice-moonlake-immunotherapeutics-hit-with-securities-fraud-investigation-due-to-drug-trial-results-contact-bfa-law\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"MLTX INQUIRY NOTICE: MoonLake Immunotherapeutics Hit with Securities Fraud Investigation Due to Drug Trial Results — Contact BFA Law","datePublished":"2025-10-08T12:30:56+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mltx-inquiry-notice-moonlake-immunotherapeutics-hit-with-securities-fraud-investigation-due-to-drug-trial-results-contact-bfa-law\/"},"wordCount":402,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mltx-inquiry-notice-moonlake-immunotherapeutics-hit-with-securities-fraud-investigation-due-to-drug-trial-results-contact-bfa-law\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU0MTg3NSM3MTg0NzA1IzIyOTA5OTU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mltx-inquiry-notice-moonlake-immunotherapeutics-hit-with-securities-fraud-investigation-due-to-drug-trial-results-contact-bfa-law\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/mltx-inquiry-notice-moonlake-immunotherapeutics-hit-with-securities-fraud-investigation-due-to-drug-trial-results-contact-bfa-law\/","name":"MLTX INQUIRY NOTICE: MoonLake Immunotherapeutics Hit with Securities Fraud Investigation Due to Drug Trial Results - Contact BFA Law - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mltx-inquiry-notice-moonlake-immunotherapeutics-hit-with-securities-fraud-investigation-due-to-drug-trial-results-contact-bfa-law\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mltx-inquiry-notice-moonlake-immunotherapeutics-hit-with-securities-fraud-investigation-due-to-drug-trial-results-contact-bfa-law\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU0MTg3NSM3MTg0NzA1IzIyOTA5OTU=","datePublished":"2025-10-08T12:30:56+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mltx-inquiry-notice-moonlake-immunotherapeutics-hit-with-securities-fraud-investigation-due-to-drug-trial-results-contact-bfa-law\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/mltx-inquiry-notice-moonlake-immunotherapeutics-hit-with-securities-fraud-investigation-due-to-drug-trial-results-contact-bfa-law\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mltx-inquiry-notice-moonlake-immunotherapeutics-hit-with-securities-fraud-investigation-due-to-drug-trial-results-contact-bfa-law\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU0MTg3NSM3MTg0NzA1IzIyOTA5OTU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU0MTg3NSM3MTg0NzA1IzIyOTA5OTU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mltx-inquiry-notice-moonlake-immunotherapeutics-hit-with-securities-fraud-investigation-due-to-drug-trial-results-contact-bfa-law\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"MLTX INQUIRY NOTICE: MoonLake Immunotherapeutics Hit with Securities Fraud Investigation Due to Drug Trial Results — Contact BFA Law"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/893691","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=893691"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/893691\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=893691"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=893691"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=893691"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}